Published: 12. June, 2026
Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children …
Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children
- CT004 targets post-anaesthetic agitation and emergence delirium, an underserved paediatric condition affecting 25-30% of children, for which no approved treatments are currently available.
- A phase II study of 676 children at five sites in Denmark has been initiated and funded by University Hospital of Copenhagen, Rigshospitalet.
- Cessatech retains worldwide commercial rights to CT004.
Copenhagen, Denmark – 12 June 2026 – Cessatech A/S, a late-stage paediatric specialty company developing and commercializing hospital medicines for children, today announced a new collaboration with the University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous melatonin-based therapy for the prevention and management of post-anaesthetic agitation and emergence delirium in children, hereafter named CT004.
Link to Release and CT004 introduction
